Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Metachromatic Leukodystrophy
Interventions
DRUG

Warfarin

Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5

Trial Locations (1)

08103

Cooper University Hospital, Camden

All Listed Sponsors
lead

The Cooper Health System

OTHER

NCT00683189 - Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy | Biotech Hunter | Biotech Hunter